Literature DB >> 16872258

Current status of antiretroviral therapy.

Zelalem Temesgen1, David Warnke, Mary J Kasten.   

Abstract

At present, there are 22 FDA-approved antiretroviral agents, which are categorised into four classes of drugs. Several others are in various stages of basic and clinical development. The authors of this paper review the general characteristics of each class of antiretrovirals, as well as individual investigational agents that are in advanced clinical development. A brief synopsis of US and WHO antiretroviral treatment guidelines is also provided.

Mesh：

Substances：

Year:  2006        PMID： 16872258     DOI： 10.1517/14656566.7.12.1541

Source DB:  PubMed          Journal:  Expert Opin Pharmacother        ISSN： 1465-6566            Impact factor:   3.889


  19 in total

1.  Effect of the active site D25N mutation on the structure, stability, and ligand binding of the mature HIV-1 protease.

Authors:  Jane M Sayer; Fengling Liu; Rieko Ishima; Irene T Weber; John M Louis
Journal:  J Biol Chem       Date:  2008-02-15       Impact factor: 5.157

Review 2.  Small molecule inhibitors of the HIV-1 virulence factor, Nef.

Authors:  Thomas E Smithgall; Gary Thomas
Journal:  Drug Discov Today Technol       Date:  2013-12

3.  Molecular binding mode of PF-232798, a clinical anti-HIV candidate, at chemokine receptor CCR5.

Authors:  Ya Zhu; Yan-Long Zhao; Jian Li; Hong Liu; Qiang Zhao; Bei-Li Wu; Zhen-Lin Yang
Journal:  Acta Pharmacol Sin       Date:  2018-06-25       Impact factor: 6.150

4.  Characterization of antiviral activity of benzamide derivative AH0109 against HIV-1 infection.

Authors:  Liyu Chen; Zhujun Ao; Kallesh Danappa Jayappa; Gary Kobinger; Shuiping Liu; Guojun Wu; Mark A Wainberg; Xiaojian Yao
Journal:  Antimicrob Agents Chemother       Date:  2013-05-13       Impact factor: 5.191

5.  Tight-Binding Hydroxypyrazole HIV-1 Nef Inhibitors Suppress Viral Replication in Donor Mononuclear Cells and Reverse Nef-Mediated MHC-I Downregulation.

Authors:  Haibin Shi; Colin M Tice; Lori Emert-Sedlak; Li Chen; Wing Fai Li; Marianne Carlsen; Jay E Wrobel; Allen B Reitz; Thomas E Smithgall
Journal:  ACS Infect Dis       Date:  2019-12-16       Impact factor: 5.084

6.  Synthesis and evaluation of orally active small molecule HIV-1 Nef antagonists.

Authors:  Lori A Emert-Sedlak; H Marie Loughran; Haibin Shi; John L Kulp; Sherry T Shu; Jielu Zhao; Billy W Day; Jay E Wrobel; Allen B Reitz; Thomas E Smithgall
Journal:  Bioorg Med Chem Lett       Date:  2016-01-21       Impact factor: 2.823

7.  Cross-clade inhibition of recombinant human immunodeficiency virus type 1 (HIV-1), HIV-2, and simian immunodeficiency virus SIVcpz reverse transcriptases by RNA pseudoknot aptamers.

Authors:  Daniel M Held; Jay D Kissel; Sarah J Thacker; Daniel Michalowski; Dayal Saran; Jianfei Ji; Richard W Hardy; John J Rossi; Donald H Burke
Journal:  J Virol       Date:  2007-02-28       Impact factor: 5.103

8.  Impact of human immunodeficiency virus type 1 resistance to protease inhibitors on evolution of resistance to the maturation inhibitor bevirimat (PA-457).

Authors:  Catherine S Adamson; Kayoko Waki; Sherimay D Ablan; Karl Salzwedel; Eric O Freed
Journal:  J Virol       Date:  2009-03-11       Impact factor: 5.103

9.  Effector kinase coupling enables high-throughput screens for direct HIV-1 Nef antagonists with antiretroviral activity.

Authors:  Lori A Emert-Sedlak; Purushottam Narute; Sherry T Shu; Jerrod A Poe; Haibin Shi; Naveena Yanamala; John Jeff Alvarado; John S Lazo; Joanne I Yeh; Paul A Johnston; Thomas E Smithgall
Journal:  Chem Biol       Date:  2013-01-24

Review 10.  Virus maturation as a new HIV-1 therapeutic target.

Authors:  Catherine S Adamson; Karl Salzwedel; Eric O Freed
Journal:  Expert Opin Ther Targets       Date:  2009-08       Impact factor: 6.902
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.